Navigation Links
Nektar Therapeutics Announces Third Quarter 2007 Financial Results

SAN CARLOS, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today the company's financial results for the third quarter that ended September 30, 2007.

Revenue totaled $56.3 million in the third quarter of 2007 compared to $58.6 million in the third quarter of 2006. For the nine months ended September 30, 2007, Nektar reported total revenue of $207.3 million compared to $147.8 million in the same period in 2006.

Cash, cash equivalents, and short-term investments were $452.6 million at September 30, 2007 compared to $406.8 million at June 30, 2007.

Nektar reported a net loss of $18.6 million or $0.20 per share in the third quarter of 2007 compared to a net loss of $19.6 million or $0.22 per share in the same period of 2006.

For the nine months ended September 30, 2007, net loss was $71.8 million or $0.78 per share compared to a net loss of $115.9 million or $1.29 per share in the same period in 2006.

"We've made great progress reshaping Nektar this year," said Howard W. Robin, president and chief executive officer of Nektar. "We realigned the company's business and research activities around our PEGylation and pulmonary technology platforms, built a strong executive team, signed a new strategic partnership with Bayer, and are moving two proprietary programs into Phase 2 clinical trials. Finally, for the first time in Nektar's history, we expect almost no operating cash burn for the year."

Mr. Robin will host a conference call today for analysts and investors beginning at 2:00 p.m. Pacific time to discuss the company's performance. This conference call will be available via webcast and can be accessed through a link that is posted on the Investor Relations section of the Nektar website, The web broadcast of the conference call will be available for replay through November 14, 2007.

To access the conference call, follow these instructions:

Dial: (800) 299-6183 (U.S.); (617) 801-9713 (international)

Passcode: 21153437 (Howard Robin is the host)

Audio replay dial-in and passcode:

Dial: (888) 286-8010 (U.S.);(617) 801-6888 (international)

Passcode: 86766898

About Nektar

Nektar Therapeutics is a biopharmaceutical company with a mission to develop and enable differentiated therapeutics with its industry-leading pulmonary and PEGylation technology platforms. Nektar pulmonary and PEGylation technology, expertise, manufacturing capabilities and know-how have enabled ten approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its pulmonary and PEGylation technology platforms to

existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements that reflect the company's current views as to its financial plan, expectations regarding the progress, potential, and clinical plans for the company's proprietary product candidates in clinical development, the value of the company's technology platforms, business development potential with respect to potential future partnerships and overall prospects for the company's business. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) the company's proprietary product candidates and those of certain of its partners are in the early phases of clinical development and the risk of failure is high and can occur at any stage prior to regulatory approval, (ii) the timing or success of the commencement or end of clinical trial phases is subject to a number of uncertainties including but not limited to patient enrollment, regulatory requirements and clinical outcomes, the company's or its partner's ability to obtain regulatory approval of its proprietary product candidates, (iii) the company's or its partner's success in obtaining regulatory approvals for product candidates, (iv) the company may not successfully complete new collaborative arrangements with respect to our product candidates, or if any arrangements we do negotiate do not include sufficiently favorable commercial terms, we may not receive an adequate return on these investments and our results of operations and financial condition would suffer (v) the company's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or intellectual property licenses from third parties may be required in the future, and (vi) the outcome of any existing or future intellectual property or other litigation related to the company's proprietary product candidates. Other important risks and uncertainties are detailed in the company's reports and other filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

Tim Warner, 650-283-4915

Stephan Herrera, 415-488-7699

Jennifer Ruddock, 650-631-4954



(In thousands, except per share information)

Unaudited Unaudited

Three-Months Ended Nine-Months Ended

September 30, September 30,

2007 2006 2007 2006


Product sales and royalties $37,497 $43,521 $159,818 $103,564

Contract research 18,824 15,111 47,436 44,250

Total revenue 56,321 58,632 207,254 147,814

Operating costs and expenses:

Cost of goods sold 27,457 31,179 123,469 76,947

Research and development 35,773 36,005 114,265 106,860

General and administrative 12,426 13,422 42,339 60,878

Litigation Settlement - - - 17,710

Impairment of long lived

assets - - - 1,156

Amortization of other

intangible assets 237 708 710 3,331

Total operating costs and

expenses 75,893 81,314 280,783 266,882

Loss from operations (19,572) (22,682) (73,529) (119,068)

Interest income 5,519 6,060 16,444 17,316

Interest expense (4,773) (5,255) (14,408) (15,335)

Other Income 206 2,273 189 1,181

Loss before provision for income

taxes (18,620) (19,604) (71,304) (115,906)

Provision for income taxes - - (500) -

Net loss $(18,620) $(19,604) $(71,804) $(115,906)

Basic and diluted net loss per

share $(0.20) $(0.22) $(0.78) $(1.29)

Shares used in computing basic

and diluted net loss per share 92,028 90,017 91,764 89,550



(In thousands)

September 30, December 31,

2007 2006

(unaudited) (1)


Current assets:

Cash and cash equivalents $174,713 $63,760

Short-term investments 277,931 394,880

Accounts receivable, net of

allowance 36,805 47,148

Inventory 17,175 14,656

Other current assets 8,147 14,595

Total current assets 514,771 535,039

Long-term investments - 8,337

Property and equipment, net 135,317 133,812

Goodwill 78,431 78,431

Other intangible assets, net 2,917 3,626

Other assets 6,849 8,932

Total assets $738,285 $768,177


Current liabilities:

Accounts payable $4,421 $7,205

Accrued compensation 11,796 12,994

Accrued expenses 24,564 17,942

Interest payable 1,130 3,814

Capital lease obligations, current

portion 1,134 711

Deferred revenue, current portion 43,636 16,409

Convertible subordinated notes,

current portion 66,627 102,653

Other current liabilities 3,371 3,586

Total current liabilities 156,679 165,314

Convertible subordinated notes 315,000 315,000

Capital lease obligations 21,987 19,759

Deferred revenue 58,247 23,697

Other long-term liabilities 15,469 17,347

Total liabilites 567,382 541,117

Commitments and contingencies

Stockholders' equity:

Preferred stock - -

Common stock 9 9

Capital in excess of par value 1,299,173 1,283,982

Accumulated other comprehensive

income 518 62

Accumulated deficit (1,128,797) (1,056,993)

Total stockholders' equity 170,903 227,060

Total liabilities and stockholders'

equity $738,285 $768,177

(1) The consolidated balance sheet at December 31, 2006 has been derived

from the audited financial statements at that date but does not

include all of the information and notes required by generally

accepted accounting principles in the United States for complete

financial statements. Certain 2006 amounts have been reclassified

between line items to conform with the 2007 presentation.

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
(Date:4/25/2017)... ... April 25, 2017 , ... A stressful work environment ... can also decrease overall productivity and performance in the workplace. The goal of Clearview ... the last few weeks of April, Clearview Resolution Services will be shutting down the ...
(Date:4/25/2017)... ... April 25, 2017 , ... A ... student test score performance for the 2015-16 school year across Wisconsin’s public schools, ... Though it highlights important patterns in student test score performance, the report’s limited ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is ... using Invisalign® in Lutz, FL. With the help of this highly-effective, yet ... with fewer potential complications, more discretion and less pain. , Drs. Sarah Jockin, ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... , ... Back Pain Centers of America (BPC), which connects people ... their area, announces the launch of a new and proprietary customer relationship management (CRM) ... reputable physicians to help them with back or neck pain and helps to match ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... April 24, 2017 Solentim, the developer ... the addition of a major new product line ... Seeding,). The VIPS has been developed for automatically ... microplates as part of the process to generate ... simple and more reliable solution when compared to ...
(Date:4/20/2017)... 20, 2017  Vivify Health, the pioneer and market ... awarded a very significant patent for the advancement of ... care via digital health.  This landmark patent provides the ... further secures Vivify,s position as the leader in remote ... the first company to apply consumer mobile devices, wireless ...
(Date:4/20/2017)... MARLBOROUGH, Mass. , April 20, 2017 /PRNewswire/ ... company developing innovative therapeutics that address significant unmet ... new data from the Company,s consumer product development ... technology, at the Society for Investigative Dermatology (SID) ... is to advance and promote the sciences relevant ...
Breaking Medicine Technology: